Virtual ADC & Bioconjugation Symposium – December 2-3, 2020

- Learn about advancements in drug development, drug-linker technologies and product characterization.
- Get perspectives on successful strategies for your ADC and bioconjugation programs.
- Tackle today’s challenges and discuss solutions with your peers.
- Clinical-Stage GlycoConnect™ Technology as a Powerful Platform to Generate ADCs and Bispecific Antibodies, Dr. R. van Geel, Synaffix
- Taming random conjugation: producing monodisperse ADCs from native antibodies, Dr. S. Kolodych, Syndivia
- The Benefits of Using Orthogonal Analytics in ADC Drug Development, Dr. D. Galbraith, Merck KGaA, Darmstadt, Germany
- Commercializing antibody-drug conjugates: a CMO’s journey, Elizabeth Mc Kee and Jeff Carroll
- Payloads to Accelerate the ADC Clinical Path, Dr. D. Goddel, Merck KGaA, Darmstadt, Germany
- MORAb-202, a Folate Receptor Alpha-targeted Antibody-drug Conjugate, loaded with HALAVEN® (eribulin) as payload, Dr. T. Uenaka, Eisai Inc.
- Payloads to Accelerate the ADC Clinical Path, Dr. D. Goddel, Merck KGaA, Darmstadt, Germany
- Engineered AvibodiesTM (improved Diabodies) precisely loaded with novel ADC payloads that surpass IgG-ADCs in cancer therapy, Dr. P. Hudson, Avipep
- ABL202/LCB71: a ROR1-targeting antibody-drug conjugate for treating TNBC and CLL, Dr. J. Jung, ABL Bio
- The Benefits of Using Orthogonal Analytics in ADC Drug Development, Dr. D. Galbraith, Merck KGaA, Darmstadt, Germany
- Register for Virtual HPAPI Technical Symposium – June 2, 2022 - May 16, 2022
- Virtual ADC & Bioconjugation Symposium – December 2-3, 2020 - November 2, 2020